| # | Drug | Count |
|---|---|---|
| 0 | RITUXIMAB | 443 |
| 1 | CYCLOPHOSPHAMIDE | 414 |
| 2 | DOXORUBICIN | 389 |
| 3 | PREDNISONE | 319 |
| 4 | DEXAMETHASONE | 187 |
| 5 | DEXAMETHASONE 1.5 MG | 187 |
| 6 | CYTARABINE | 150 |
| 7 | ETOPOSIDE | 142 |
| 8 | DOXORUBICIN HYDROCHLORIDE | 137 |
| 9 | PREDNISOLONE | 136 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | POLATUZUMAB VEDOTIN | 44 | 0.0549 |
| 1 | DOXORUBICIN | 389 | 0.0092 |
| 2 | IFOSFAMIDE | 80 | 0.0072 |
| 3 | VINCRISTINE SULFATE | 112 | 0.0070 |
| 4 | ETOPOSIDE PHOSPHATE | 5 | 0.0057 |
| 5 | DOXORUBICIN HYDROCHLORIDE | 137 | 0.0056 |
| 6 | COPANLISIB | 1 | 0.0055 |
| 7 | PLATINUM | 1 | 0.0048 |
| 8 | CYTARABINE | 150 | 0.0047 |
| 9 | CYCLOPHOSPHAMIDE | 414 | 0.0046 |
| # | Drug class | Count |
|---|---|---|
| 0 | Corticosteroid [EPC] | 507 |
| 1 | CD20-directed Cytolytic Antibody [EPC] | 447 |
| 2 | Alkylating Drug [EPC] | 440 |
| 3 | Platinum-based Drug [EPC] | 222 |
| 4 | Nucleoside Metabolic Inhibitor [EPC] | 153 |
| 5 | Topoisomerase Inhibitor [EPC] | 142 |
| 6 | Folate Analog Metabolic Inhibitor [EPC] | 111 |
| 7 | Thalidomide Analog [EPC] | 55 |
| 8 | Nonsteroidal Anti-inflammatory Drug [EPC] | 36 |
| 9 | Platelet Aggregation Inhibitor [EPC] | 36 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | CD20-directed Cytolytic Antibody [EPC] | 447 | 0.0036 |
| 1 | Topoisomerase Inhibitor [EPC] | 142 | 0.0035 |
| 2 | Alkylating Drug [EPC] | 440 | 0.0031 |
| 3 | Platinum-based Drug [EPC] | 222 | 0.0016 |
| 4 | Echinocandin Antifungal [EPC] | 4 | 0.0012 |
| 5 | Hematopoietic Stem Cell Mobilizer [EPC] | 1 | 0.0012 |
| 6 | Nucleoside Metabolic Inhibitor [EPC] | 153 | 0.0010 |
| 7 | Corticosteroid [EPC] | 507 | 0.0007 |
| 8 | Antiprotozoal [EPC] | 4 | 0.0006 |
| 9 | Monobactam Antibacterial [EPC] | 1 | 0.0006 |